Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Zai Lab Ltd ADR
(NQ:
ZLAB
)
15.91
+0.17 (+1.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zai Lab Ltd ADR
< Previous
1
2
3
4
Next >
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
April 15, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
April 11, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
April 02, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Limited (NASDAQ:ZLAB) Investor Alert: Investigation over Potential Wrongdoing
November 15, 2023
San Diego, CA -- (SBWIRE) -- 11/15/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Zai Lab Limited.
Via
SBWire
Zai Lab Limited (NASDAQ:ZLAB) Investor Notice: Investigation over Possible Violations of Securities Laws
July 31, 2023
San Diego, CA -- (SBWIRE) -- 07/31/2023 -- Zai Lab Limited is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
April 01, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
March 27, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
March 13, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
March 06, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in March Investor Conference
March 06, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
February 27, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
January 25, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
January 10, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in January Investor Conference
December 19, 2023
From
Zai Lab Limited
Via
Business Wire
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
December 13, 2023
From
Paratek Pharmaceuticals, Inc.
Via
GlobeNewswire
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
December 12, 2023
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
November 07, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in November Investor Conferences
October 26, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
October 18, 2023
- Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
September 18, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
August 30, 2023
Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in September Investor Conferences
August 29, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
August 07, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Bowlero, and Chegg and Encourages Investors to Contact the Firm
August 06, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 26, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 21, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
July 20, 2023
- Company to Host Conference Call and Webcast on August 8, 2023, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
July 19, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 16, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.